HRP20131021T1 - Novi 7-deazapurin nukleozidi za terapijske uporabe - Google Patents

Novi 7-deazapurin nukleozidi za terapijske uporabe Download PDF

Info

Publication number
HRP20131021T1
HRP20131021T1 HRP20131021AT HRP20131021T HRP20131021T1 HR P20131021 T1 HRP20131021 T1 HR P20131021T1 HR P20131021A T HRP20131021A T HR P20131021AT HR P20131021 T HRP20131021 T HR P20131021T HR P20131021 T1 HRP20131021 T1 HR P20131021T1
Authority
HR
Croatia
Prior art keywords
compound according
pharmaceutically acceptable
hydrogen
mixture
acceptable salt
Prior art date
Application number
HRP20131021AT
Other languages
English (en)
Croatian (hr)
Inventor
Aurelie Bourderioux
Michal Hocek
Petr Naus
Original Assignee
Institute Of Organic Chemistry And Biochemistry As Cr, V.V.I.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute Of Organic Chemistry And Biochemistry As Cr, V.V.I. filed Critical Institute Of Organic Chemistry And Biochemistry As Cr, V.V.I.
Publication of HRP20131021T1 publication Critical patent/HRP20131021T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HRP20131021AT 2009-04-22 2010-04-19 Novi 7-deazapurin nukleozidi za terapijske uporabe HRP20131021T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17165609P 2009-04-22 2009-04-22
PCT/CZ2010/000050 WO2010121576A2 (en) 2009-04-22 2010-04-19 Novel 7-deazapurine nucleosides for therapeutic uses

Publications (1)

Publication Number Publication Date
HRP20131021T1 true HRP20131021T1 (hr) 2014-01-31

Family

ID=42768153

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20131021AT HRP20131021T1 (hr) 2009-04-22 2010-04-19 Novi 7-deazapurin nukleozidi za terapijske uporabe

Country Status (15)

Country Link
US (3) US9321800B2 (https=)
EP (1) EP2421879B1 (https=)
JP (2) JP5721275B2 (https=)
CN (2) CN102459300B (https=)
AU (3) AU2010238985B2 (https=)
CA (2) CA2966647A1 (https=)
DK (1) DK2421879T3 (https=)
ES (1) ES2437917T3 (https=)
HR (1) HRP20131021T1 (https=)
MX (1) MX2011011160A (https=)
NZ (2) NZ700583A (https=)
PL (1) PL2421879T3 (https=)
PT (1) PT2421879E (https=)
SI (1) SI2421879T1 (https=)
WO (1) WO2010121576A2 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102459300B (zh) * 2009-04-22 2014-12-10 捷克有机化学和生物化学研究院 用于治疗用途的新的7-脱氮嘌呤核苷
AU2010330823A1 (en) * 2009-12-18 2012-07-05 Joslin Diabetes Center, Inc. Beta-cell replication promoting compounds and methods of their use
CN102319254B (zh) * 2011-07-20 2013-06-19 上海交通大学 5-碘代杀菌核素在制备抗肿瘤药物中的应用
CZ305466B6 (cs) * 2013-11-04 2015-10-14 Ústav organické chemie a biochemie Akademie věd České republiky, v. v. i. Substituované 7-deazapurinové ribonukleosidy pro terapeutické použití
ES2792036T3 (es) 2014-11-14 2020-11-06 Nerviano Medical Sciences Srl Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de cinasa
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
EP4491236A3 (en) 2016-05-10 2025-04-02 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
EP3454862B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
CA3029170C (en) 2016-06-29 2021-02-16 Ustav Organicke Chemie A Biochemie Av Cr, V.V.I. Substituted thienopyrrolopyrimidine ribonucleosides for therapeutic use
CZ307334B6 (cs) 2016-08-02 2018-06-13 Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v.v.i. Substituované heteropentadieno-pyrrolopyrimidinové ribonukleosidy pro terapeutické použití
US11168090B2 (en) 2017-01-18 2021-11-09 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors
EP4717317A2 (en) 2017-06-20 2026-04-01 C4 Therapeutics, Inc. N/o-linked degrons and degronimers for protein degradation
US11072628B2 (en) 2017-10-19 2021-07-27 Universiteit Gent Nucleoside analogues for the treatment of parasitic infections
WO2019143991A1 (en) * 2018-01-18 2019-07-25 Array Biopharma Inc. SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS AS RET KINASE INHIBITORS
CN111615514B (zh) 2018-01-18 2022-10-11 奥瑞生物药品公司 作为ret激酶抑制剂的取代的吡唑并[4,3-c]吡啶化合物
EP3740491A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
CZ308104B6 (cs) 2018-03-12 2020-01-08 Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v. v. i. Pyridinopyrrolopyrimidinové ribonukleosidy pro terapeutické použití
WO2020033288A1 (en) * 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3849986B1 (en) 2018-09-10 2022-06-08 Array Biopharma, Inc. Fused heterocyclic compounds as ret kinase inhibitors
MX2021015772A (es) * 2019-06-18 2022-01-31 Taiho Pharmaceutical Co Ltd Compuesto de carbonato novedoso que tiene esqueleto de pirrolopirimidina o sal farmaceuticamente aceptable del mismo.
WO2021164848A1 (en) * 2020-02-17 2021-08-26 Katholieke Universiteit Leuven Novel 6-substituted 7-deazapurines and corresponding nucleosides as medicaments
KR102639275B1 (ko) * 2021-06-08 2024-02-21 퓨쳐메디신 주식회사 다중 표적 인산화효소 저해 활성을 갖는 뉴클레오사이드 유도체 및 이를 포함하는 암의 예방 및 치료용 약학적 조성물
WO2023052468A1 (en) 2021-09-28 2023-04-06 Universiteit Antwerpen Nucleoside analogues for the treatment of parasitic infections

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL108523A0 (en) * 1993-02-03 1994-05-30 Gensia Inc Pharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain
WO2002057425A2 (en) * 2001-01-22 2002-07-25 Merck & Co., Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
AU2002353165A1 (en) * 2001-12-17 2003-06-30 Ribapharm Inc. Deazapurine nucleoside libraries and compounds
AU2003232071A1 (en) * 2002-05-06 2003-11-17 Genelabs Technologies, Inc. Nucleoside derivatives for treating hepatitis c virus infection
US20040157892A1 (en) 2003-02-12 2004-08-12 Crompton Co./Cie Pesticidal fluoroethyl pyrazoles
JP2007509939A (ja) * 2003-10-27 2007-04-19 ジェネラブズ テクノロジーズ インコーポレーティッド ウイルス感染を治療するためのヌクレオシド化合物
US7202223B2 (en) * 2003-10-27 2007-04-10 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
EP1682564A1 (en) * 2003-10-27 2006-07-26 Genelabs Technologies, Inc. METHODS FOR PREPARING 7-(2 -SUBSTITUTED-s-D-RIBOFURANO SYL)-4-(NR2R3)-5-(SUBSTITUTED ETHYN-1-YL)-PYRROLO 2,3-D|PYRIMIDINE DERIVATIVES
EP1781101A2 (en) * 2004-07-29 2007-05-09 Metabasis Therapeutics, Inc. Novel nucleoside derivatives
CN101977923B (zh) * 2008-01-18 2014-10-08 捷克有机化学和生物化学研究院 抑制细胞生长的7-脱氮嘌呤核苷
NZ590005A (en) * 2008-06-23 2012-06-29 Janssen Pharmaceutica Nv Piperidyl acrylamide antogonists of ccr2
GB0815968D0 (en) * 2008-09-03 2008-10-08 Angeletti P Ist Richerche Bio Antiviral agents
CN102459300B (zh) * 2009-04-22 2014-12-10 捷克有机化学和生物化学研究院 用于治疗用途的新的7-脱氮嘌呤核苷

Also Published As

Publication number Publication date
CA2759131A1 (en) 2010-10-28
CN104497084A (zh) 2015-04-08
AU2015205885B2 (en) 2017-04-06
US20150218201A1 (en) 2015-08-06
EP2421879B1 (en) 2013-09-04
JP5721275B2 (ja) 2015-05-20
CN102459300B (zh) 2014-12-10
NZ700583A (en) 2016-04-29
US9321800B2 (en) 2016-04-26
US10294262B2 (en) 2019-05-21
NZ596301A (en) 2014-10-31
HK1209129A1 (en) 2016-03-24
CN104497084B (zh) 2018-06-05
AU2017204148A1 (en) 2017-07-06
AU2015205885A1 (en) 2015-09-03
US9624257B2 (en) 2017-04-18
ES2437917T3 (es) 2014-01-15
DK2421879T3 (da) 2013-11-25
CA2966647A1 (en) 2010-10-28
AU2017204148B2 (en) 2018-12-06
AU2010238985A1 (en) 2011-12-01
JP6087889B2 (ja) 2017-03-01
WO2010121576A3 (en) 2011-06-16
PL2421879T3 (pl) 2014-02-28
US20160318970A1 (en) 2016-11-03
CA2759131C (en) 2017-06-20
SI2421879T1 (sl) 2014-01-31
EP2421879A2 (en) 2012-02-29
HK1166325A1 (en) 2012-12-14
PT2421879E (pt) 2013-12-09
CN102459300A (zh) 2012-05-16
JP2012524731A (ja) 2012-10-18
JP2015013901A (ja) 2015-01-22
US20170240584A1 (en) 2017-08-24
MX2011011160A (es) 2012-01-27
AU2010238985B2 (en) 2015-04-23
WO2010121576A2 (en) 2010-10-28

Similar Documents

Publication Publication Date Title
HRP20131021T1 (hr) Novi 7-deazapurin nukleozidi za terapijske uporabe
HRP20171957T1 (hr) Derivati 2-(2,4,5-supstituiranog-anilino) pirimidina kao modulatori egfr koji su korisni za liječenje raka
JP2017528524A5 (https=)
PH12019500830A1 (en) 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer
HRP20191268T1 (hr) Derivati tieno[2,3-c]pirol-4-ona kao inhibitori erk
ME02638B (me) Inhibitori replikacije virusa gripa
BR112015023705A8 (pt) compostos, composições farmacêuticas, usos de um composto, e método para síntese do composto da fórmula (ia)
HRP20201727T1 (hr) 2-((5-(1-(3-(metilsulfonil)propil)piperidin-4-il)piridin-2-il)amino)pirido[2,3-d]pirimidin-7(8h)-on derivati i srodni spojevi kao cdk4 inhibitori za liječenje tumora
NI201000003A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas.
EA201100030A1 (ru) Пиразольные соединения 436
GT201300137A (es) Derivados de imidazo [1,2-b] piridazina e imidazo [4,5-b] piridina como inhibidores de jak
UY31254A1 (es) Derivados sutituidos de n4-(5-metil-1h-pirazol-3-il)- 1,3,5-triazina-2,4-diamina, sus enantiómeros, sales farmacéuticamente aceptables de los mismos, composiciones, procesos de preparación y aplicaciones
PE20091321A1 (es) Derivados biciclicos de carboxamidas aza-biciclicas, su preparacion y su aplicacion en terapeutica
ECSP109935A (es) Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o pi3k
HRP20191617T1 (hr) Kombinacija koja sadrži inhibitor mek i inhibitor b-raf
UA115320C2 (uk) Інгібітори кінази
CL2012002318A1 (es) Compuestos derivados de tieno [2,3-d]pirimidina, inhibidores de quinasa mnk1 y mnk2; composición farmaceutica; que los comprende; y su uso en el tratamiento de enfermedades metabolicas, hematopoyeticas, neurodegenerativas, renales, inflamatorias y cancer.
JP2016532667A5 (https=)
JP2015512943A5 (https=)
HRP20150030T1 (hr) Derivati pirazolokinolina kao inhibitori dna-pk
EA201070327A1 (ru) Катехоламиновые производные и их пролекарства
MX2009008386A (es) Derivados de 2-amino-5,7-dihidro-6h-pirrolo[3,4-d] pirimidina como inhibidores de proteinas de choque termico-90 para tratar cancer.
SV2009003389A (es) Compuestos de pirido [2,3-d] pirimidina-7-ona como inhibidores de p13k-alfa para el tratamiento del cancer
MX2009010165A (es) Nuevas imidazo[4,5-b]piridina-7-carboxamidas 704.
ECSP099767A (es) Derivados de n' - (fenil) -n- (morfolin-4-il-piridin-2-il) -pirimidina-2, 4-diamina como inhibidores de quinasas ephb4 para el tratamiento de afecciones proliferativas